Abstract: Little has been published about the impact of different HT formulations or ways of administration on gynecological cancer risk.
INTRODUCTION
There have been many complex discussions surrounding the role of steroid hormone formulations since their introduction as treatment, which point to both benefits and risks in short and long-term use [1] . Hormone therapy (HT) became a hot issue with the publication of the Women's Health Initiative (WHI) Study [2, 3] .
We have shown no increased risk for OvC or UC cancers in our own publications, and in fact even weak evidence for a reduced risk in young women using oral contraceptives [4, 5] .
Many earlier studies reported no significantly increased or decreased risk of ovarian cancer for ever use of HT [6] [7] [8] [9] [10] [11] [12] [13] . The same applies for the risk of UC with use of opposed HT [14] [15] [16] [17] [18] . The WHI study reported no significantly increased risk of ovarian or uterine cancer [2, 3] but only for preparations containing conjugated equine estrogens. Recently Beral et al. [19] [20] demonstrated that long-term use of HT was associated with a slightly increased or decreased risk of OvC, i.e. significantly or non-significantly across different publications. This was similar concerning use of continuous-combined HT and endometrial cancer. For HT with cyclically added progestins the relative risk of UC was significantly higher. But the debate about the risk of OvC and UC associated with HT use seems still open, and in particular little is known about the relative merits or risks of different progestins and ways of administration for either OvC or UC [21] .
This publication presents data on ovarian and uterine corpus cancer risk associated with ever and current use of HT of different preparations and administrations in all age groups and postmenopausal women.
MATERIALS AND METHODOLOGY
The study method has been published earlier [21] . In brief: The objective of this study was to analyze possible differences in risk for two gynecological cancers associated with different HT formulations using a case-control design in collaboration with German cancer registries and tumor centers (see acknowledgements). The population covered was defined by the location of the participating cancer registries/tumor centers, i.e. in Northern Germany (Hamburg, Approvals were obtained (Ethical Committees; Office of Data Privacy). Constraints imposed by ethical and data privacy rules suggested that the tumor registries should identify cases without providing names/addresses and should facilitate contact with cases directly or via the treating physicians (including posting questionnaires). There was only one letter to living cancer cases asking for participation and providing the self-administered questionnaire, i.e. no reminder was sent in case of non-response. The number of diseased cases or number of non-responders was not provided to the investigators who received only the completed questionnaires from responders.
The lifetime history of exposure to sex steroid hormones was recorded by month and year of exposure (type, brand name). This information was compiled on the basis of selfreported information by the women (see below).
Eligible cases were histologically confirmed malignant neoplasm of the ovary (ICD 10: C56) and of the corpus uteri (ICD 10: C54), i.e. in accordance with the definition from the IARC Cancer Registry [23] , diagnosed between 2000 and 2004 in women of all age groups. At the time of the intended interview, subjects had to be alive and in sufficiently good condition (decided by physicians or tumor centers/registries) and willing to participate in the study, i.e. to complete the questionnaire. This information was not given to the investigators (see above).
For ovarian cancer, a potential total of 911 cases who had been identified and contacted by the tumor centers/registries and who were willing to participate then sent the completed questionnaires back. But only 777 OvC cases could be used for the analysis because 134 cases were excluded for different reasons: in 15 cases the diagnosis was not fully confirmed, and 119 had another cancer in the same time frame as OvC. The relevant information for UC cases was: 1148 UC cases returned completed questionnaires. 1026 UC cases could be analyzed and 122 cases were excluded: 21 were not fully confirmed diagnoses and 101 had another cancer in the same time frame as UC. As the cancer of the uterine corpus most likely to be affected by HT due to its hormone sensitivity, endometrial carcinoma constitutes about 80% of all uterine corpus cancers (for review see Clement and Young, Advances in Anatomic Pathology, 9(3):145-84, 2002). We therefore abstained from subgroup analysis based on the non-reviewable registry data concerning histological subtype.
Up to five eligible controls (with uterus and ovary) were matched for each cancer case in terms of age (same year of birth +/-two years) and area of residence (same state/Bundesland) by using a large, population-based pool of women [22] . Of a total of 18,898 potential controls, we matched 3211 controls for 777 OvC cases and 3668 controls for 1026 UC cases. These HT categories are not mutually exclusive for analysis of ever use. Therefore, comparison of risk estimates across exposure groups of ever use can be used only as a first impression as to whether there are substantial differences or not. We also refrained from defining HT categories in terms of "longest used during lifetime" because of the arbitrary character of this decision and the problem of what "longest" might mean across different HT formulations and modes of administration.
Data Collection, Variables and Database Preparation
We distinguished in the analyses between four subgroups of cancer cases and controls: all women, women in the postmenopausal phase, and this for ever users and current users of HT.
It was not always clear if a woman is in the postmenopausal phase or not. Post-menopause was assumed when the women reported permanent cessation of menstruation. But if this information was missing or unclear or if the woman was currently taking HT, menopause was assumed if her age was over 52 years.
Index Dates
An index date was introduced to limit a possible protopathic bias. We focused on a lag-time of 0.5 years before diagnosis in order to avoid the possible effect of information related to a perceived OvC or UC risk immediately preceding the final cancer diagnosis.
The Analytic Model
Conditional logistic regression was used as primary analysis. Crude and adjusted odds ratios (OR) were reported with 95% confidence intervals (95% CI). Adjustment variables were BMI, family history of ovarian cancer, childbearing history, age at first live birth, duration of breastfeeding, age at menarche, OC use, and education. Missing values of adjustment variables were rare but if so they were imputed to allow the analysis. For sub-group analyses of HT categories, we additionally adjusted for age and residency because the matching effect might be lost in individual subgroups.
Moreover, we refrained from complex adjustment in HTsubgroup analyses to prevent unstable risk estimates. In addition, a cell suppression rule was applied if any cell of the "two-by-two" table contained fewer than 5 women, i.e. no odds ratio was calculated then.
We analyzed the impact of duration of HT use compared to never use (categories: < 2 years, 2-4 years, 5-7 years, and 8+ years), and similarly for the time elapsed from first HT use to the manifestation of cancer (1-4 years, 5-9 years, 10-14 years, 15+ years) as well as for the time since last use (1-2 years, 3-4 years, and 5+ years ago). Short use (less than 1 year) might be differently recalled by women with cancer versus those without cancer (particularly if longer ago).
The statistical packages SAS 9.1 and STATA 8.0 were used. Table 1 shows the OvC and UC cases and matched controls with respect to a list of potential risk factors. Many parameters with significant association were found for OvC and UC risk, respectively: Age over 50 years (OR = 2.1 and OR = 8.1 for OvC and UC), high educational level (OR = 0.8 and OR = 0.7), higher age at menarche (OR = 0.9 (non-sign.) and 0. Most of these variables were significant effect modifiers of the association between HT exposure and gynecological cancer risk.
RESULTS

Case/Non-Case Characteristics
Ever, Current vs Never HT Use
All risk estimates for OvC and UC cancer were analyzed for ever and current users of HT, i.e. for all women and postmenopausal women. In all subgroups, the results pointed toward reduced risk ( Table 2 ) ranging from OR 0.7 to 0.9.
The OvC risk was significantly reduced for HT ever and current use in all and post-menopausal women.
A significantly reduced risk of UC was observed for ever use in the subgroup of all women; the risk estimates of other subgroups were non-significantly reduced. of OvC and UC in ever and current users were lower than unity (OR=1.0) but often statistically non-significant for all and for postmenopausal women.
Time-Related Exposure
There was no meaningful trend showing that longer duration of HT use was significantly associated with change in UC risk for all and post-menopausal women, and for ever and current use. However, there might be a slightly increasing OvC trend with longer duration of current HT use. This might not be clinically relevant because all risk estimates were under 1.0. Not clear is the meaning of a marginally increased risk for UC that was observed in the first duration of use category (< 2 years).
There was also no meaningful temporal trend of risk associated with increasing time since first use, i.e. both for OvC and UC risk. With the exception of two time categories, most showed decreased ORs, some of which were significantly decreased.
Cancer Risk Across Different HT Formulations
The aim of the analysis of different HT formulation groups was to provide a crude, visual comparison of OvC and UC risk estimates across different HT categories. Once again, it should be emphasized that ever-use HT categories are not mutually exclusive. Table 3 contains risk estimates for OvC and UC (OR and 95% confidence interval) by HT formulations and ways of administration. Most of the risk estimates for both gynecological cancers were lower than unity (<1.0), although not all are statistically significant in the subgroups of all and postmenopausal ever and current HT users.
The oral route of administration was dominant among our study participants. Oral HT ever use showed a significantly decreased OvC and UC risk associated with hormone use in all and postmenopausal women. Conditional logistic regression analysis [Odds ratios (OR) and 95% confidence intervals]; adjustment for BMI, family history of uterine cancer, childbearing history, age at first live birth, duration of breast-feeding, age at menarche, ever OC use, education. Index date 0.5 = exposure information was not considered 0.5 year prior to cancer diagnosis. 1 E-case, e-ctrl = number of observations for exposed cases and exposed controls. 2 Time variables were rounded.
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Transdermal application and other forms of administration showed mainly non-significant OvC and UC risk estimates across all subgroups.
Ever use of both sequential and continuous-combined HT formulations showed significantly reduced OvC and UC risk estimates across all subgroups including current use.
No obvious or meaningful difference in risk of OvC and UC was found between women ever having or currently using HT with CEE + MPA (alone or together) across all subgroups.
No substantial or meaningful differences in OvC and UC risk were observed among the categories with different estrogens progestins across the four subgroups. The point estimates were mainly lower than unity and many statistically insignificant, but often compromised by small numbers. Estrogens and progestins not listed in Table 3 were not frequent enough to calculate risk estimates for OvC and UC (see methods: "cell suppression rule").
DISCUSSION
Cancer of the ovary and uterine corpus result in substantial morbidity and mortality even though they are not among the most frequent neoplasms: OvC is the seventh most common female cancer in the ranking worldwide and uterine corpus cancer the eighth most common cancer in women according to an expert review by the American Institute of Cancer Research [24] .
For ovarian cancer, these experts suggest that the following parameters play a role as risk factors: Obesity increased risk in some but not all studies; a higher number of pregnancies is associated with reduced risk; and OC use is possibly linked with a lower total number of ovulations [24] . It is also known that most ovarian cancers have estrogen receptors, and therefore a relation with external hormone use could be plausible [25] . However, in a review published in 2002, no satisfactory conclusion about OvC risk related to HT was obtained: five studies found a slightly increased risk but 15 did not observe an increased risk for ovarian cancer associated with HT [26] . Conditional logistic regression: Odds ratios (OR) and 95% confidence intervals (95% CI); adjusted only for age and residency. e-cas= exposed cases; e-ctrl= exposed controls; n.d. = no data (cell suppression rule).
We found consistency with the literature concerning risk factors for OvC. Ever being pregnant (OR=0.39) and OC use (OR= 0.46) showed the expected reduction of OvC risk. Similar results showing significantly reduced risk for ovarian cancer were reported by a large Danish case-control study (554 cases and 1566 controls) [27] : ever pregnant (OR=0.4), with increasing number of pregnancies (OR=0.9), older age at last pregnancy (OR=0.9 per 5 years), and ever use of OCs (OR=0.7).
For uterine corpus cancer, the above-mentioned expert panel considered all potential risk factors, including among others a prolonged high internal or external exposure to estrogens when unopposed by progestins [24] . Thus, early age at menarche or late menopause may constitute an increased risk, whereas pregnancy and high parity reduce the risk. This confirms what we observed. The mechanism by which hormonal factors may affect carcinogenesis at different gynecological sites was considered unclear [24] . A newer publication [28] suggested some explanations for different proliferative activity of different hormone formulations depending on different estrogen and other receptors differently stimulated by HTs.
The similarity of risk factors (including effects of exogenous hormones) in OvC and UC, and also across more or less all non-communicable diseases is striking and gives rise to speculation about non-specific, non-causal associations with gynecological tumors [29] , for example. Given the great potential for residual confounding and bias, even a statistically significant small association might be inconclusive, because such associations could well be situated below reliable resolution levels of the "epidemiological microscope", i.e. it is not possible to discriminate between causation and bias/confounding [25, 29, 30] .
Overall, we found no clinically meaningful OvC risk for ever and current users of HT, and even a significantly decreased OvC risk on the basis of 777 cases of ovarian cancer Conditional logistic regression: Odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age and region. e-case = exposed cases; e-ctrl = exposed controls; n.d. = no data (cell suppression rule).
compared with 3211 matched controls. A result with a similar order of magnitude was reported by Hempling 1997 [6] , but Beral 2007 [19] reported an increased risk of developing OvC for current users.
Our current case-control study confirms the results of our recently published nested case-control study that showed at least no increased risk of ovarian cancer associated with HT use, although with small numbers [31] .
There is still no consensus as to whether a slightly decreased or increased OvC risk is associated with HT use [7, 11, 12, 13, 19, 32] . Some authors report decreased and others increased risk estimates, particularly after long periods of use [8] . A collaborative re-analysis of four European casecontrol studies from 1984 to 1994 [10] was based on relatively small samples of cases in the individual studies (n=112, 152, 971, and 235 respectively). The authors of this review calculated increased OvC risk estimates associated with ever use of HT ranging from 1.4 to 1.8 -all but one study were not significant. After pooling the studies, the risk became -as expected -significantly increased due to higher numbers [10] . Many US case-control studies showed no association of HT use with ovarian cancer [9] , but others presented some increased ovarian cancer risk [25, 33, 34] . Discussion has suggested that this difference could be due to different user patterns or types of HT, or simply a chance finding notwithstanding the often discussed problem of statistical significance and clinical relevance [10] . No significantly increased risk of ovarian cancer was reported in the WHI [2, 3] and HERS studies [35] ; however, the numbers were too small to draw conclusions.
We observed no meaningful trend in the OvC risk with increasing duration of use in ever users and also in the subgroup of postmenopausal women. There might be a slightly increasing OvC risk trend with longer duration in current users of HT. We consider this to be not clinically relevant because all risk estimates are less than 1.0.
The focus of our study, however, was to detect possible differences in OvC risk across different HT formulations or ways of administration in ever or current users. But no meaningful differences were observed. Taken at face value, the point estimates for HT use would be compatible with a decreased risk of ovarian cancer. For some of the progestins, the small numbers prevented conclusions other than no clinically relevant differences being detectable.
We found no clinically meaningful UC risk in users of "estrogen plus progestin" (E+P) hormone treatment, or even a significantly decreased UC risk on the basis of 1026 cases of uterine corpus cancer compared with 3668 matched controls.
In other case-control studies, the relative risk of uterine cancer was usually not increased. In a meta-analysis of 30 studies, opposed estrogen treatment (E+P) showed little if any risk; i.e. many risk estimates were observed well below 1.0 [36] . Later reviews confirmed the view of no increased risk of endometrial cancer in users of opposed HT [37] [38] [39] .
In a recent review, case-control and cohort studies have been broadly consistent concerning the risk estimates for endometrial cancer and contraceptive use [40] . In an earlier meta-analysis, however, cohort studies showed a lower risk than case-control studies [36] . Our current case-control study confirms the results of our recently published nested casecontrol study that showed no increased risk of uterine cancer [41] .
Moreover and in contrast to breast cancer, no increased risk of uterine corpus cancer was reported in the WHI [2, 13] or HERS studies [35] . The Million Women Study [42] found a significantly reduced risk of endometrial cancer in women with last use of continuous combined preparations (RR 0.71), and not significantly associated with cyclic combined HT formulations (RR 1.05). We observed for both forms of E+P combinations mainly significant reduced risk of UC. This was indirectly supported by a recent Cochrane review which stated that "the addition of progestagens, either in continuous-combined or sequential regimens, helped to prevent the development of endometrial hyperplasia" [43] . Moreover, it was also stressed that particular continuouscombined regimens may have no or even a protective effect on the endometrium [16] .
The distribution of UC risk for different HT formulation or administration categories is compatible with the notion that no obvious differences were observed. Almost all point estimates were below unity (1.0). Taken at face value, the point estimates for HT use would be compatible with a decreased risk of uterine corpus cancer. For some of the progestins, the small numbers prevented us from drawing any strong conclusions. It is our understanding, however, that no clinically relevant differences among different progestins were detectable.
Possible Limitations of the Study
In general, case-control studies like other observational studies are prone to bias and residual confounding. It cannot be excluded that self-selection of cases is a problem in our study. We cannot offer information about non-response or selection of surviving cases by cancer registry/tumor centers due to design. If there is a bias -which we do not assumeit might be even differential regarding exposure status. A possible source of recall bias is the use of a self-administered questionnaire without visual aids, although it is our experience that recall is relatively accurate regarding hormone use in women. It is our assumption that the results of our study have not been substantially affected by differential selfselection or recall bias, although we cannot exclude these possibilities.
Analysis of the effect of external hormones on ovarian and uterine corpus cancer must take into account the lag time in cancer development, although it is difficult for observational studies to account sufficiently for time-dependence. Lag time is likely to be long and may vary depending on complex unknown causal mechanisms, and is therefore an issue involving complex, time-dependent risk factors. However, we could not account for the latent period because we had no chance to determine the interval between tumor induction and diagnosis.
Another exposure-related problem is the focus on detecting differences in the risk of OvC and UC across different exposure categories, i.e. HT formulations and ways of administration in ever users. These categories were not mutual exclusive since one can use more than one HT with more than one way of administration over a period of years. This potential problem seems not to be serious in our study, because a comparison with current HT use, where this problem does not exist, showed conclusions in the same direction.
A less likely but potential source of bias is the diagnostic suspicion bias even for serious diseases such as cancer. Nobody can be sure that early stage tumor cases are equally identified (diagnosed) among HT users and non-users. This, however, would not explain the reduced risk estimates for OvC and UC observed. In addition, the possibility cannot be excluded e.g. that the women and/or their physicians were aware of "warning signs" (e.g. bleedings) that may have led to the decision not to use HT in the year prior to final OvC or UC diagnosis. This exposure indication bias may have worked differentially, i.e. more often in later confirmed cancer cases than in controls. Stratification by index dates (increasing lag times) should have helped us to cope with such a problem.
Moreover, observational studies with "state-of-the-art" performance face an important methodological problem if the observed risk estimates are small. Given the great potential for residual confounding and different undetected forms of bias, even a statistically significant small positive or inverse association cannot be ruled out and the results might be inconclusive. Such small associations could well be situated below reliable resolution levels of the "epidemiological microscope", i.e. it is not possible to differentiate between causation and bias/confounding [14, 30] .
Therefore, the interpretation of the OvC and UC risk estimates observed in our case-control study should be taken with care.
CONCLUSIONS
Ever and current use of HT was at least not associated with an increased risk of ovarian and uterine corpus cancer, either in all or in post-menopausal women. Obviously, the decreased risk estimates did not vary markedly among different HT subgroups. However, the small numbers and the overlapping nature of the HT formulation subgroups of everuse suggests cautious interpretation. Moreover, there might be differences that were not detectable in our study due to the "limited solution of the epidemiological microscope".
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